Valuation: Novavax, Inc.

Market Cap 1.6B 1.4B 1.29B 1.2B 2.28B 153B 2.31B 15.47B 6.02B 74.99B 6.01B 5.88B 260B P/E 2026 *
-20.6x
P/E 2027 * -38.3x
Enterprise Value 1.82B 1.59B 1.47B 1.36B 2.59B 174B 2.62B 17.58B 6.84B 85.25B 6.84B 6.69B 296B EV / Sales 2026 *
4.44x
EV / Sales 2027 * 7.37x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day-3.80%
1 week+0.37%
Current month-0.27%
1 month+8.99%
3 months+17.88%
6 months+26.28%
Current year+39.81%
1 week 9.13
Extreme 9.13
10.12
1 month 8.26
Extreme 8.265
10.12
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap.
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
-3.90%+0.37%+42.13%+33.07% 1.6B
+1.08%+7.56%+4.01%+9.84% 49.92B
-0.08%-1.78%+415.95%+622.14% 40.23B
-0.18%+6.84%+27.12%-5.12% 34.55B
+4.17%+6.88%+28.61%+63.61% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-1.57%+2.48% - - 17.05B
+0.65%+4.44%+75.12%+138.67% 15.92B
-0.95%+0.76%+13.97%+21.59% 13.86B
+2.26%+3.61%+100.11%+100.20% 13.52B
Average -0.35%+6.52%+78.98%+112.91% 24.73B
Weighted average by Cap. +0.10%+6.47%+94.40%+140.08%

Financials

2026 *2027 *
Net sales 410M 359M 331M 307M 583M 39.11B 591M 3.96B 1.54B 19.2B 1.54B 1.51B 66.55B 258M 226M 208M 194M 368M 24.65B 372M 2.5B 971M 12.1B 971M 949M 41.96B
Net income -79.31M -69.46M -63.97M -59.38M -113M -7.56B -114M -766M -298M -3.71B -298M -291M -12.87B -43.22M -37.85M -34.87M -32.36M -61.46M -4.12B -62.29M -417M -162M -2.02B -162M -159M -7.02B
Net Debt 219M 192M 177M 164M 311M 20.89B 316M 2.11B 823M 10.25B 822M 804M 35.55B 303M 266M 245M 227M 431M 28.92B 437M 2.93B 1.14B 14.2B 1.14B 1.11B 49.22B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
06/07/26 $9.385 -3.64% 1,997,827
02/07/26 $9.740 +2.96% 4,850,708
01/07/26 $9.460 +0.42% 4,568,968
30/06/26 $9.420 +0.64% 3,984,674
29/06/26 $9.360 +5.41% 4,039,729
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.740USD
Average target price
14.11USD
Spread / Average Target
+44.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock